Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lacorwen-S is a natural homeopathic medicinal product developed by Weber & Weber Biologische Arzneimittel, specifically formulated to address nervous heart complaints and functional cardiovascular disturbances. The preparation is a combination of several active ingredients, including Crataegus (Hawthorn), Selenicereus grandiflorus (Night-blooming cereus), Spigelia anthelmia (Pinkroot), and Kalium carbonicum (Potassium carbonate). Crataegus is well-regarded in phytotherapy for its cardiotonic properties, believed to enhance coronary blood flow and myocardial contractility, potentially through the inhibition of 3',5'-cyclic-nucleotide phosphodiesterases. Selenicereus grandiflorus and Spigelia anthelmia are traditionally used in homeopathic medicine to manage symptoms such as heart palpitations, chest tightness, and irregular rhythms associated with nervous exhaustion. As an approved medicine in Germany, Lacorwen-S is typically administered as oral drops to support cardiac efficiency and alleviate symptoms of autonomic cardiac regulation disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lacorwen-S.